Skip to content
Preprint · OA via OpenAlex

Microglial Foxo3 shapes dopaminergic vulnerability in Parkinson’s disease

Baptiste Texier, Sarah Roudaud, Quentin Husson, Morgane Prime, Marie Alma, Lisaydi Dominguez-Coronado, David Frieser, Anne-Louise Le Dorze, Margot Zahm, Anne-Laure Iscache, Daniel Alvarez‐Fischer, Anne S. Dejean, Bernard Klonjkowski, Stéphane Hunot, Séverine Fruchon

bioRxiv (Cold Spring Harbor Laboratory) · 2026

Abstract

Abstract Neurodegenerative diseases such as Parkinson’s disease (PD) result from complex interactions between neuronal stress and the surrounding tissue environment, yet the determinants that govern this interplay remain incompletely understood. While neuronal responses to mitochondrial dysfunction(definition) and proteotoxic stress have been extensively characterized, the contribution of the microglial state to disease progression remains unclear. Here, we identify the transcription factor Foxo3 as a key regulator of dopaminergic vulnerability acting predominantly through microglia-, rather than neuron-intrinsic, mechanisms. Foxo3 was rapidly induced and translocated to the nucleus in dopaminergic-like cells in response to mitochondrial complex I inhibition and α-synuclein aggregation, indicating activation of a conserved neuronal stress response. However, neuron-specific deletion of Foxo3 attenuated early Parkinson-like transcriptional signatures but did not confer sustained in vivo neuroprotection. In contrast, microglia-specific deletion of Foxo3 provided robust and durable protection against dopaminergic degeneration across complementary mouse models, including both MPTP intoxication and α-synuclein–driven pathology. Translatomic profiling revealed that Foxo3 deficiency induces extensive transcriptional remodeling of microglia at baseline, establishing a distinct state enriched in immune-related and phagocytic pathways that remains compatible with tissue homeostasis. Strikingly, neuroprotection occurred despite minimal transcriptional reprogramming following neurotoxic insult, suggesting that disease outcome is dictated by the baseline microglial state rather than by the magnitude of transcriptional responses to neurotoxic insult. Mechanistically, neuroprotection correlated with selective modulation of discrete signaling nodes, including reinforcement of the TREM2-TYROBP axis and attenuation of pathways involved in intracellular signal amplification, rather than with broad suppression of inflammatory programs. These findings indicate that Foxo3 does not primarily regulate the magnitude of microglial activation, but instead defines the baseline configuration and response thresholds that shape subsequent neuroimmune dynamics. Together, our results identify baseline microglial state as a determinant of neurodegenerative trajectory and position Foxo3 as a central regulator of this process. More broadly, these findings provide a framework in which microglial state-setting, rather than the magnitude of reactive responses alone, governs dopaminergic vulnerability, with potential implications for therapeutic strategies targeting neuroimmune interactions in Parkinson’s disease.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.64898/2026.05.22.727098
Canonical
link ↗
Fetched
2026-10-23 MST

Cite this

APA
Texier, B., Roudaud, S., Husson, Q., Prime, M., Alma, M., Dominguez-Coronado, L., Frieser, D., Dorze, A.L., Zahm, M., Iscache, A., Alvarez‐Fischer, D., Dejean, A.S., Klonjkowski, B., Hunot, S., Fruchon, S., &amp; Szelechowski, M. (2026). Microglial Foxo3 shapes dopaminergic vulnerability in Parkinson’s disease. <em>bioRxiv (Cold Spring Harbor Laboratory)</em>. https://doi.org/10.64898/2026.05.22.727098
Vancouver
Texier B, Roudaud S, Husson Q, Prime M, Alma M, Dominguez-Coronado L, et al. Microglial Foxo3 shapes dopaminergic vulnerability in Parkinson’s disease. bioRxiv (Cold Spring Harbor Laboratory). 2026. doi:10.64898/2026.05.22.727098.
BibTeX
@unpublished{baptiste2026Microg, title = {Microglial Foxo3 shapes dopaminergic vulnerability in Parkinson’s disease}, author = {Baptiste Texier and Sarah Roudaud and Quentin Husson and Morgane Prime and Marie Alma and Lisaydi Dominguez-Coronado and David Frieser and Anne-Louise Le Dorze and Margot Zahm and Anne-Laure Iscache and Daniel Alvarez‐Fischer and Anne S. Dejean and Bernard Klonjkowski and Stéphane Hunot and Séverine Fruchon and Marion Szelechowski}, journal = {bioRxiv (Cold Spring Harbor Laboratory)}, year = {2026}, doi = {10.64898/2026.05.22.727098}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings